Long-term safety of paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease: the SPARTAN DCB study.

Ioannis MerinopoulosTharusha GunawardenaUpul WickramarachchiPaul RichardsonClint MaartSulfi SreekumarChris SawhTrevor WistowToomas SarevAlisdair RydingTim GilbertAris PerperoglouVassilios S VassiliouSimon C Eccleshall

Published in: Clinical research in cardiology : official journal of the German Cardiac Society (2020)

We found no evidence of late mortality associated with DCB angioplasty compared with non-paclitaxel second-generation DES in up to 5 years follow-up. DCB is a safe option for the treatment of de novo coronary artery disease.

Keyphrases

coronary artery disease
cardiovascular events
percutaneous coronary intervention
coronary artery bypass grafting
risk factors
heart failure
type diabetes
combination therapy
atrial fibrillation
chemotherapy induced
adverse drug
replacement therapy
smoking cessation